Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000649063 | SCV000770888 | likely benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2024-01-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002449072 | SCV002734495 | uncertain significance | Cardiovascular phenotype | 2024-03-06 | criteria provided, single submitter | clinical testing | The p.E365G variant (also known as c.1094A>G), located in coding exon 7 of the FLNC gene, results from an A to G substitution at nucleotide position 1094. The glutamic acid at codon 365 is replaced by glycine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003144434 | SCV003833104 | uncertain significance | not provided | 2019-07-03 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003144434 | SCV004224102 | uncertain significance | not provided | 2022-12-21 | criteria provided, single submitter | clinical testing |